Focus on Lipids Care

Back to articles

Icosapent ethyl reduces ischemic events in patients with hypertriglyceridemia

KEY POINT

Patients with hypertriglyceridemia on statin therapy who received icosapent ethyl (Vascepa—Amarin) had a significant reduction in adverse cardiovascular (CV) events compared with patients receiving placebo, according to results of the REDUCE-IT trial published in the New England Journal of Medicine.